General Information of the Drug (ID: M6APDG04322)
Name
ADC-03
Status
Preclinical
TTD Drug ID
D0AN9V
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Herpesvirus ubiquitin-specific protease (HAUSP)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Herpesvirus ubiquitin-specific protease (HAUSP) is a therapeutic target for ADC-03. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ADC-03 through regulating the expression of Herpesvirus ubiquitin-specific protease (HAUSP). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Herpesvirus ubiquitin-specific protease (HAUSP) is a therapeutic target for ADC-03. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ADC-03 through regulating the expression of Herpesvirus ubiquitin-specific protease (HAUSP). [2], [3]
References
Ref 1 The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. Biochem Biophys Res Commun. 2019 May 7;512(3):479-485. doi: 10.1016/j.bbrc.2019.03.093. Epub 2019 Mar 21.
Ref 2 Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opin Ther Pat. 2015;25(10):1191-1208. doi: 10.1517/13543776.2015.1056737. Epub 2015 Jun 16.
Ref 3 Methyltransferase-like 3 Aggravates HCC Development via Mediating N6-Methyladenosine of Ubiquitin-Specific Protease 7. J Oncol. 2022 May 5;2022:6167832. doi: 10.1155/2022/6167832. eCollection 2022.